• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 205

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study...

PTSF85 – Ahmad Doroudian, Ph.D. of BetterLife Pharma and Dr. Abid...

Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human...

Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments

MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent...

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for...

Eyes on Oregon, a Psychedelics Today Podcast with Jon Dennis and...

Filament Health Announces Co-Development and Exclusive Licensing Agreement with Entheotech Bioscience

Psychedelic Bypassing: When Avoidance is Mistaken for Healing

1...204205206...303Page 205 of 303

EDITOR PICKS

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©